• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VLA
Click for more information
0.00% $1.75

VIRALYTICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
VLA Positive CAVATAK Combination Data Presented at US MeetingPRICE SENSITIVE07/11/14
VLA Annual Report to shareholders24/10/14
VLA Appendix 4C - quarterlyPRICE SENSITIVE24/10/14
VLA Notice of Annual General Meeting/Proxy Form24/10/14
VLA Change of Company Secretary24/10/14
VLA Viralytics Investor Presentation21/10/14
VLA Details of Share Registry address15/10/14
VLA CAVATAK Immunotherapy Combo shows more Anti-cancer ActivityPRICE SENSITIVE30/09/14
VLA Date of 2014 Annual General Meeting29/09/14
VLA Updated positive data from Phase 2 Melanoma trial of CAVATAKPRICE SENSITIVE29/09/14
VLA Updated CAVATAK Results to be presented at ESMO CongressPRICE SENSITIVE17/09/14
VLA Change in substantial holding10/09/14
VLA Initial Director's Interest Notice - Dr McColl and Mr Turvey09/09/14
VLA Final Director's Interest Notice - Dr Atman and Mr Molloy09/09/14
VLA Peter Turvey appointed to Viralytics board08/09/14
VLA Appendix 3B01/09/14
VLA VLA Full Year Financial Results and Operational Highlights27/08/14
VLA Appendix 4E and Financial ReportPRICE SENSITIVE27/08/14
VLA Letter to Shareholders - Viralytics Newsletter July 201430/07/14
VLA Appendix 4C - quarterlyPRICE SENSITIVE22/07/14
VLA Viralytics Limited - Updated Securities Trading Policy19/06/14
VLA +Ceasing to be a substantial holder - HHL11/06/14
VLA Change in substantial holding11/06/14
VLAViralytics - Progress in CAVATAK Phase 2 Melanoma TrialPRICE SENSITIVE03/06/14
HHL +Becoming a substantial holder from HHA27/05/14
VLACAVATAK Phase 2 Trial Update - ASCO Conference presentation15/05/14
VLAAppendix 4C - quarterlyPRICE SENSITIVE29/04/14
VLAAppendix 3B24/04/14
VLACAVATAK activity in lung cancer - international conferencePRICE SENSITIVE14/04/14
VLAPositive Interim Phase 2 Trial Results for CAVATAKPRICE SENSITIVE08/04/14
VLAChange of Director's Interest Notice28/03/14
VLAChange of Director's Interest Notice17/03/14
VLAViralytics - International Institutional Ownership17/03/14
VLABecoming a substantial holder14/03/14
VLABecoming a substantial holder14/03/14
VLABecoming a substantial holder14/03/14
VLABecoming a substantial holder14/03/14
VLACleansing Notice - section 708A(5)(e) Corporations Act13/03/14
VLAViralytics completes $27 million Fund RaisingPRICE SENSITIVE13/03/14
VLAAppendix 3B13/03/14
VLAVLA to Present at US Institutional Investor Forums07/03/14
VLAResults of Meeting06/03/14
VLAGeneral Meeting 6 March 2014 - CEO Presentation06/03/14
VLACAVATAK anti-cancer activity - US Cancer Conference April06/03/14
VLAViralytics commences STORM phase 1/2 clinical trialPRICE SENSITIVE06/03/14
VLAAppendix 3B05/03/14
VLAViralytics $4.1m Entitlement Offer closes fully subscribed28/02/14
VLAHalf Yearly Report and AccountsPRICE SENSITIVE19/02/14
VLAViralytics Limited - Letter to ineligible shareholders11/02/14
VLAViralytics Limited - despatch of information booklet11/02/14
VLACleansing Notice05/02/14
VLAViralytics expands patent coverage in the USPRICE SENSITIVE04/02/14
VLANotice of General Meeting/Proxy Form03/02/14
VLAViralytics entitlement offer letter to eligible shareholders30/01/14
VLAViralytics Limited - Additional Placement Details30/01/14
VLAViralytics - Capital Raising - letter to option holders30/01/14
VLAViralytics Limited - Investor Presentation30/01/14
VLAViralytics - Cleansing Notice - 708AA Corporations Act30/01/14
VLAAppendix 3B30/01/14
VLAViralytics - Entitlement Offer - Information BookletPRICE SENSITIVE30/01/14
VLAViralytics - Capital Raising up to $27 millionPRICE SENSITIVE30/01/14
VLAAppendix 4C - quarterlyPRICE SENSITIVE29/01/14
VLATrading HaltPRICE SENSITIVE28/01/14
VLATarget enrolment achieved - CAVATAK Phase 2 Melanoma TrialPRICE SENSITIVE08/01/14
VLADetails of Company Address18/12/13
VLALeading US Oncologist joins Scientific Advisory Board27/11/13
VLAResults of Meeting19/11/13
VLACEO Report to the Annual General Meeting19/11/13
VLAChairman's Address to Shareholders19/11/13
VLAInvestor & Shareholder Presentation08/11/13
VLAFurther strong progress in CAVATAK phase 2 CALM trialPRICE SENSITIVE08/11/13
VLAViralytics receives $1.9 million R&D Tax IncentivePRICE SENSITIVE23/10/13
VLANotice of Annual General Meeting/Proxy Form18/10/13
VLAAppendix 4C - quarterlyPRICE SENSITIVE18/10/13
VLAAnnual Report to shareholders18/10/13
VLAPrimary Endpoint Achieved in CAVATAK Phase 2 Melanoma TrialPRICE SENSITIVE18/09/13
VLAViralytics receives MHRA approval for UK Clinical TrialPRICE SENSITIVE11/09/13
VLAResponse to ASX Price QueryPRICE SENSITIVE30/08/13
VLAViralytics Full Year Financial ResultsPRICE SENSITIVE28/08/13
VLAViralytics Patent Coverage ExpandedPRICE SENSITIVE07/08/13
VLAViralytics Commences Trading on US OTCQX Marketplace05/08/13
VLAInvestor and Shareholder Presentation23/07/13
VLAStrong interim results of CAVATAK in Phase 2 TrialPRICE SENSITIVE19/07/13
VLACompany Secretary Appointment/Resignation17/07/13
VLAAppendix 4C - quarterlyPRICE SENSITIVE17/07/13
VLACAVATAK anticancer activity in bladder cancer modelPRICE SENSITIVE18/06/13
VLACAVATAK presentations at international OV conference17/06/13
VLAASCO Poster and CALM Trial Milestone AchievedPRICE SENSITIVE04/06/13
VLAProgress of CAVATAK phase II trial to be presented at ASCO16/05/13
VLAShareholder Newsletter01/05/13
VLAChairman's role26/04/13
VLAAppendix 4C - quarterlyPRICE SENSITIVE16/04/13
VLAPositive results for Viralytics CAVATAK phase 1 IV StudyPRICE SENSITIVE09/04/13
VLACAVATAK featured in presentation at US Oncology Conference25/03/13
VLAViralytics comment on results from Amgen Phase 3 trialPRICE SENSITIVE22/03/13
VLAAcceleration of Patient Recruitment in Phase 2 StudyPRICE SENSITIVE21/03/13
VLAChange of facsimile number07/03/13
VLADetails of Company Address27/02/13
VLAAppendix 4D and Half Year ReportPRICE SENSITIVE18/02/13
VLAAppendix 3B08/02/13
VLA Positive CAVATAK Combination Data Presented at US Meeting
07/11/14PRICE SENSITIVE
VLA Annual Report to shareholders
24/10/14
VLA Appendix 4C - quarterly
24/10/14PRICE SENSITIVE
VLA Notice of Annual General Meeting/Proxy Form
24/10/14
VLA Change of Company Secretary
24/10/14
VLA Viralytics Investor Presentation
21/10/14
VLA Details of Share Registry address
15/10/14
VLA CAVATAK Immunotherapy Combo shows more Anti-cancer Activity
30/09/14PRICE SENSITIVE
VLA Date of 2014 Annual General Meeting
29/09/14
VLA Updated positive data from Phase 2 Melanoma trial of CAVATAK
29/09/14PRICE SENSITIVE
VLA Updated CAVATAK Results to be presented at ESMO Congress
17/09/14PRICE SENSITIVE
VLA Change in substantial holding
10/09/14
VLA Initial Director's Interest Notice - Dr McColl and Mr Turvey
09/09/14
VLA Final Director's Interest Notice - Dr Atman and Mr Molloy
09/09/14
VLA Peter Turvey appointed to Viralytics board
08/09/14
VLA Appendix 3B
01/09/14
VLA VLA Full Year Financial Results and Operational Highlights
27/08/14
VLA Appendix 4E and Financial Report
27/08/14PRICE SENSITIVE
VLA Letter to Shareholders - Viralytics Newsletter July 2014
30/07/14
VLA Appendix 4C - quarterly
22/07/14PRICE SENSITIVE
VLA Viralytics Limited - Updated Securities Trading Policy
19/06/14
VLA +Ceasing to be a substantial holder - HHL
11/06/14
VLA Change in substantial holding
11/06/14
VLAViralytics - Progress in CAVATAK Phase 2 Melanoma Trial
03/06/14PRICE SENSITIVE
HHL +Becoming a substantial holder from HHA
27/05/14
VLACAVATAK Phase 2 Trial Update - ASCO Conference presentation
15/05/14
VLAAppendix 4C - quarterly
29/04/14PRICE SENSITIVE
VLAAppendix 3B
24/04/14
VLACAVATAK activity in lung cancer - international conference
14/04/14PRICE SENSITIVE
VLAPositive Interim Phase 2 Trial Results for CAVATAK
08/04/14PRICE SENSITIVE
VLAChange of Director's Interest Notice
28/03/14
VLAChange of Director's Interest Notice
17/03/14
VLAViralytics - International Institutional Ownership
17/03/14
VLABecoming a substantial holder
14/03/14
VLABecoming a substantial holder
14/03/14
VLABecoming a substantial holder
14/03/14
VLABecoming a substantial holder
14/03/14
VLACleansing Notice - section 708A(5)(e) Corporations Act
13/03/14
VLAViralytics completes $27 million Fund Raising
13/03/14PRICE SENSITIVE
VLAAppendix 3B
13/03/14
VLAVLA to Present at US Institutional Investor Forums
07/03/14
VLAResults of Meeting
06/03/14
VLAGeneral Meeting 6 March 2014 - CEO Presentation
06/03/14
VLACAVATAK anti-cancer activity - US Cancer Conference April
06/03/14
VLAViralytics commences STORM phase 1/2 clinical trial
06/03/14PRICE SENSITIVE
VLAAppendix 3B
05/03/14
VLAViralytics $4.1m Entitlement Offer closes fully subscribed
28/02/14
VLAHalf Yearly Report and Accounts
19/02/14PRICE SENSITIVE
VLAViralytics Limited - Letter to ineligible shareholders
11/02/14
VLAViralytics Limited - despatch of information booklet
11/02/14
VLACleansing Notice
05/02/14
VLAViralytics expands patent coverage in the US
04/02/14PRICE SENSITIVE
VLANotice of General Meeting/Proxy Form
03/02/14
VLAViralytics entitlement offer letter to eligible shareholders
30/01/14
VLAViralytics Limited - Additional Placement Details
30/01/14
VLAViralytics - Capital Raising - letter to option holders
30/01/14
VLAViralytics Limited - Investor Presentation
30/01/14
VLAViralytics - Cleansing Notice - 708AA Corporations Act
30/01/14
VLAAppendix 3B
30/01/14
VLAViralytics - Entitlement Offer - Information Booklet
30/01/14PRICE SENSITIVE
VLAViralytics - Capital Raising up to $27 million
30/01/14PRICE SENSITIVE
VLAAppendix 4C - quarterly
29/01/14PRICE SENSITIVE
VLATrading Halt
28/01/14PRICE SENSITIVE
VLATarget enrolment achieved - CAVATAK Phase 2 Melanoma Trial
08/01/14PRICE SENSITIVE
VLADetails of Company Address
18/12/13
VLALeading US Oncologist joins Scientific Advisory Board
27/11/13
VLAResults of Meeting
19/11/13
VLACEO Report to the Annual General Meeting
19/11/13
VLAChairman's Address to Shareholders
19/11/13
VLAInvestor & Shareholder Presentation
08/11/13
VLAFurther strong progress in CAVATAK phase 2 CALM trial
08/11/13PRICE SENSITIVE
VLAViralytics receives $1.9 million R&D Tax Incentive
23/10/13PRICE SENSITIVE
VLANotice of Annual General Meeting/Proxy Form
18/10/13
VLAAppendix 4C - quarterly
18/10/13PRICE SENSITIVE
VLAAnnual Report to shareholders
18/10/13
VLAPrimary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial
18/09/13PRICE SENSITIVE
VLAViralytics receives MHRA approval for UK Clinical Trial
11/09/13PRICE SENSITIVE
VLAResponse to ASX Price Query
30/08/13PRICE SENSITIVE
VLAViralytics Full Year Financial Results
28/08/13PRICE SENSITIVE
VLAViralytics Patent Coverage Expanded
07/08/13PRICE SENSITIVE
VLAViralytics Commences Trading on US OTCQX Marketplace
05/08/13
VLAInvestor and Shareholder Presentation
23/07/13
VLAStrong interim results of CAVATAK in Phase 2 Trial
19/07/13PRICE SENSITIVE
VLACompany Secretary Appointment/Resignation
17/07/13
VLAAppendix 4C - quarterly
17/07/13PRICE SENSITIVE
VLACAVATAK anticancer activity in bladder cancer model
18/06/13PRICE SENSITIVE
VLACAVATAK presentations at international OV conference
17/06/13
VLAASCO Poster and CALM Trial Milestone Achieved
04/06/13PRICE SENSITIVE
VLAProgress of CAVATAK phase II trial to be presented at ASCO
16/05/13
VLAShareholder Newsletter
01/05/13
VLAChairman's role
26/04/13
VLAAppendix 4C - quarterly
16/04/13PRICE SENSITIVE
VLAPositive results for Viralytics CAVATAK phase 1 IV Study
09/04/13PRICE SENSITIVE
VLACAVATAK featured in presentation at US Oncology Conference
25/03/13
VLAViralytics comment on results from Amgen Phase 3 trial
22/03/13PRICE SENSITIVE
VLAAcceleration of Patient Recruitment in Phase 2 Study
21/03/13PRICE SENSITIVE
VLAChange of facsimile number
07/03/13
VLADetails of Company Address
27/02/13
VLAAppendix 4D and Half Year Report
18/02/13PRICE SENSITIVE
VLAAppendix 3B
08/02/13
refresh Created with Sketch. REFRESH
 

Top Stories

HotCopper Highlights: Your most watched stocks for Week 48, 2024

Good afternoon, a happy end of the week, and welcome to HotCopper Highlights – I’m Jonathon Davidson. Let’s get into it.
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Parkes Au-Cu project to 'transform' Adavale Resources with key targets Adavale Resources Ltd has entered into an all-scrip acquisition of the Parkes gold and copper project in New South Wales
Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher Vitrafy Life Sciences Limited (ASX:VFY) has defied this month’s odds to become the only newly-listed Australian company to survive a surprisingly rough November (for newcomers, at least) without sagging below its IPO price.The cryopreservation biotech did give some back on Friday,...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.